Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2010 2
2011 3
2012 1
2013 5
2014 1
2015 1
2016 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Using CD4 percentage and age to optimize pediatric antiretroviral therapy initiation.
Yin DE, Warshaw MG, Miller WC, Castro H, Fiscus SA, Harper LM, Harrison LJ, Klein NJ, Lewis J, Melvin AJ, Tudor-Williams G, McKinney RE Jr; PENPACT-1 (PENTA 9/PACTG 390) Study Team. Yin DE, et al. Pediatrics. 2014 Oct;134(4):e1104-16. doi: 10.1542/peds.2014-0527. Pediatrics. 2014. PMID: 25266426 Free PMC article. Clinical Trial.
Adherence to antiretroviral therapy and acceptability of planned treatment interruptions in HIV-infected children.
Harrison L, Ananworanich J, Hamadache D, Compagnucci A, Penazzato M, Bunupuradah T, Mazza A, Ramos JT, Flynn J, Rampon O, Mellado Pena MJ, Floret D, Marczynska M, Puga A, Forcat S, Riault Y, Lallemant M, Castro H, Gibb DM, Giaquinto C; Paediatric European Network for Treatment of AIDS (PENTA) 11 Trial Team. Harrison L, et al. AIDS Behav. 2013 Jan;17(1):193-202. doi: 10.1007/s10461-012-0197-y. AIDS Behav. 2013. PMID: 22584916 Free PMC article. Clinical Trial.
The immunological and virological consequences of planned treatment interruptions in children with HIV infection.
Klein N, Sefe D, Mosconi I, Zanchetta M, Castro H, Jacobsen M, Jones H, Bernardi S, Pillay D, Giaquinto C, Walker AS, Gibb DM, De Rossi A; Paediatric European Network for Treatment of AIDS 11 Trial Team. Klein N, et al. PLoS One. 2013 Oct 23;8(10):e76582. doi: 10.1371/journal.pone.0076582. eCollection 2013. PLoS One. 2013. PMID: 24194841 Free PMC article. Clinical Trial.
HIV-1 Drug Resistance and Second-Line Treatment in Children Randomized to Switch at Low Versus Higher RNA Thresholds.
Harrison L, Melvin A, Fiscus S, Saidi Y, Nastouli E, Harper L, Compagnucci A, Babiker A, McKinney R, Gibb D, Tudor-Williams G; PENPACT-1 (PENTA 9PACTG 390) Study Team. Harrison L, et al. J Acquir Immune Defic Syndr. 2015 Sep 1;70(1):42-53. doi: 10.1097/QAI.0000000000000671. J Acquir Immune Defic Syndr. 2015. PMID: 26322666 Free PMC article. Clinical Trial.
Association of prenatal and postnatal exposure to lopinavir-ritonavir and adrenal dysfunction among uninfected infants of HIV-infected mothers.
Simon A, Warszawski J, Kariyawasam D, Le Chenadec J, Benhammou V, Czernichow P, Foissac F, Laborde K, Tréluyer JM, Firtion G, Layouni I, Munzer M, Bavoux F, Polak M, Blanche S; ANRS French Perinatal Cohort Study Group. Simon A, et al. JAMA. 2011 Jul 6;306(1):70-8. doi: 10.1001/jama.2011.915. JAMA. 2011. PMID: 21730243
Lopinavir/ritonavir monotherapy as a nucleoside analogue-sparing strategy to prevent HIV-1 mother-to-child transmission: the ANRS 135 PRIMEVA phase 2/3 randomized trial.
Tubiana R, Mandelbrot L, Le Chenadec J, Delmas S, Rouzioux C, Hirt D, Treluyer JM, Ekoukou D, Bui E, Chaix ML, Blanche S, Warszawski J; ANRS 135 PRIMEVA (Protease Inhibitor Monotherapy Evaluation) Study Group. Tubiana R, et al. Clin Infect Dis. 2013 Sep;57(6):891-902. doi: 10.1093/cid/cit390. Epub 2013 Jun 12. Clin Infect Dis. 2013. PMID: 23766338 Clinical Trial.
16 results